NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$4.43
-0.01 (-0.23 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.30
Now: $4.43
$4.68
50-Day Range
$2.12
MA: $2.38
$2.63
52-Week Range
$1.15
Now: $4.43
$6.57
Volume529,214 shs
Average Volume1.31 million shs
Market Capitalization$393.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.
OncoCyte logo

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515
Employees51
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-22,430,000.00

Miscellaneous

Market Cap$393.89 million
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable

Headlines

Oncocyte CEO discloses insider buying - Seeking Alpha
March 24, 2021 |  seekingalpha.com
Form 10-K OncoCyte Corp For: Dec 31 - StreetInsider.com
March 19, 2021 |  streetinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

235th out of 2,024 stocks

Diagnostic Substances Industry

3rd out of 32 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$4.43
-0.01 (-0.23 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Is OncoCyte a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte
or view top-rated stocks.

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for OncoCyte
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) announced its quarterly earnings data on Monday, March, 15th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02.
View OncoCyte's earnings history
.

How has OncoCyte's stock been impacted by COVID-19 (Coronavirus)?

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OCX stock has increased by 107.0% and is now trading at $4.43.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OCX?

7 brokers have issued twelve-month price objectives for OncoCyte's shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate OncoCyte's share price to reach $6.39 in the next year. This suggests a possible upside of 44.3% from the stock's current price.
View analysts' price targets for OncoCyte
or view top-rated stocks among Wall Street analysts.

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 60, Pay $312.5k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Mr. William Annett, Advisor (Age 67, Pay $673.33k)
  • Ms. Padma Sundar, Chief Commercial Officer
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Science Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 68)
  • Ms. Sara Riordan, Director of Medical Education

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (0.68%) and Penbrook Management LLC (0.25%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte
.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including Penbrook Management LLC.
View insider buying and selling activity for OncoCyte
or view top insider-selling stocks.

Which major investors are buying OncoCyte stock?

OCX stock was purchased by a variety of institutional investors in the last quarter, including Defender Capital LLC.. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte
or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $4.43.

How much money does OncoCyte make?

OncoCyte has a market capitalization of $393.89 million. The biotechnology company earns $-22,430,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does OncoCyte have?

OncoCyte employs 51 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

Where are OncoCyte's headquarters?

OncoCyte is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515 or via email at [email protected]


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.